MedTrace Logo

Laboratory Screening of Lorcaserin for Alcohol Use Disorder

NCT04396847 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2022-09-07

Study results available
· View outcomes & findings →

Summary

Heavy-drinking smokers, including those with alcohol use disorder (AUD), are at increased risk for numerous negative health outcomes relative to those who use alcohol or cigarettes only. Although heavy-drinking smokers are recognized as an important subgroup for clinical and public health interventions, there are presently no approved medications for the joint indication of alcohol reduction and smoking cessation. Based on evidence that the serotonin system plays a role in alcohol and nicotine consumption and relapse, this study aims to examine whether a serotonin medication alters alcohol and nicotine responses in smokers with AUD, informing its potential utility as a candidate therapy for this clinical subgroup.

Conditions

Interventions

DRUG

Lorcaserin Oral Tablet

Lorcasering 10mg Oral Tablet (BID)

DRUG

Placebo oral tablet

Placebo Oral Tablet (BID)

Sponsors & Collaborators

  • The Mind Research Network

    lead OTHER

Principal Investigators

  • Christian Hendershot, Ph.D. · The Mind Research Network

  • Eric Claus, Ph.D. · The Mind Research Network

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-10-25
Primary Completion
2020-02-26
Completion
2020-02-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04396847 on ClinicalTrials.gov